Biotechnology News NASONEX Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-6 out of 6 found

Current Search: nasonex: 6

Drugmakers need to rein in ads, hearing told
(Reuters) - Pharmaceutical companies need to be more responsible in touting products to consumers or else face tighter controls from Congress, a top U.S.

Democratic lawmaker said on Thursday.

Bart Stupak, at a hearing to discuss specific...

Reuters: May 8 2008 8:22PM
Matching: nasonex

Find similar documents

Schering-Plough 1Q profit drops 48 percent on buyout costs
Schering-Plough Corp.

on Wednesday reported a 48 percent plunge in first-quarter net income, due to increased spending on research, higher overhead and costs related to an acquisition its biggest ever in the prior quarter.

The maker of...

San Francisco Chronicle: Apr 23 2008 2:11PM
Matching: nasonex

Find similar documents

BC-Earns-Schering-Plough, 2nd Ld-Writethru,0395
The maker of hepatitis and cholesterol medicines and Nasonex for allergies posted net income of $253 million, or 15 cents per share, down from $543 million, or 36 cents per share in the year-ago quarter.

Excluding acquisition costs...

San Jose Mercury News: Apr 23 2008 2:03PM
Matching: nasonex

Find similar documents

Schering-Plough 1Q profit drops 48 percent on buyout costs
Schering-Plough Corp.

The maker of...

San Francisco Chronicle: Apr 23 2008 12:53PM
Matching: nasonex

Find similar documents

Schering-Plough 1Q profit drops 48 percent on buyout costs
The maker of hepatitis and cholesterol medicines and Nasonex for allergies posted net income of $291 million, or 15 cents per share, down from $565 million, or 36 cents per share in the year-ago quarter.

Excluding acquisition costs,...

San Jose Mercury News: Apr 23 2008 11:45AM
Matching: nasonex

Find similar documents

Schering-Plough 1Q profit drops 48 percent on buyout costs
KENILWORTH, N.J.

(AP) - Schering-Plough Corp.

on Wednesday reported a 48 percent plunge in first-quarter net income, due to increased spending on research, higher overhead and costs related to a huge acquisition in the prior quarter.

Sharewatch: Apr 23 2008 11:42AM
Matching: nasonex

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.